ILEX Medical Ltd.

ILEX Medical Ltd.

TTASE:ILX
4,388.00
ILA
+41.00
(+0.94%)
347.81EPS
14.07P/E
54.77BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
45.98
43.13
49.58
51.71
55.17
59.9
63.17
88.7
94.05
76.54
81.88
82.26
83.2
79.15
Basic EPS, GAAP
-2.21
2.2
3.1
2.76
3.73
4.68
6
11.3
17.51
9.05
4.55
3.48
4.97
3.48
Free Cash Flow per Basic Share
0.28
6.79
1.99
-0.19
5.47
3.4
5.34
12.75
20.21
3.67
2.53
4.32
3.83
4.12
Dividend per Share
0.08
1.84
- -
1
1.49
1.79
2.49
- -
5.32
5.32
1.92
1.36
1.22
1.99
Book Value per Share
- -
9.16
11.93
14.06
16.18
18.92
22.2
39.32
51.02
54.35
55.27
57.78
61.2
59.9
Tangible Book Value per Share
- -
0.24
5.47
8.44
11.18
14.63
18.52
36.5
48.72
51.5
52.77
55.63
59.51
58.39
Basic Weighted Avg Shares
10
10
10
10
10
10
10
11
11
11
11
11
11
11
Sales/Revenue/Turnover
461
433
497
519
554
601
634
946
1,061
863
916
920
931
885
Operating Margin (%)
-4.87
7.84
7.16
7.46
8.65
12.26
11.69
15.29
23.03
16.78
8.47
7.03
6.01
4.62
Depreciation Expense
21
21
22
22
24
25
37
40
50
50
48
49
50
49
Net Income, GAAP
-22
22
31
28
37
47
60
121
197
102
51
39
56
39
Effective Tax Rate (%)
- -
38.46
25.09
25.94
26.18
22.86
24.51
18.1
22.66
24.18
25
25.8
25.06
27.25
Profit Margin (%)
-4.81
5.11
6.25
5.33
6.76
7.82
9.5
12.74
18.61
11.83
5.55
4.24
5.97
4.39
Working Capital
- -
129
148
157
173
195
198
280
392
409
407
451
468
425
LT Debt
- -
98
70
61
45
36
53
43
46
39
36
39
33
36
Total Equity
- -
205
226
245
266
293
323
444
576
613
624
646
685
670
Return on Invested Capital (%)
- -
- -
8.49
8.96
10.94
16
15.28
25.38
32.43
18.72
9.18
7.2
6.6
5.02
Return on Capital (%)
- -
- -
10.24
8.14
9.78
12.15
14.8
25.19
34.78
15.91
7.82
5.95
8
5.74
Return on Common Equity (%)
- -
- -
29.4
21.21
24.66
26.68
29.21
36.2
38.76
17.18
8.23
6.14
8.35
5.85

Capital Structure

ILS

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
14
13
13
LT Borrowings
- -
- -
- -
LT Finance Leases
33
36
36
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
746
685
548

Working Capital

ILS

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
724
652
631
Cash, Cash Equivalents & STI
232
215
217
Accounts Receivable, Net
266
235
212
Inventories
194
183
185
Total Current Liabilities
255
224
206
Payables & Accruals
- -
- -
- -
ST Debt
14
13
13
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.22%
9.52%
5.91%
Free Cash Flow
-286.93%
2.72%
-11.36%
Net Income, GAAP
16.26%
-3.12%
42.52%
Sales/Revenue/Turnover
7.55%
0.24%
1.14%
Total Cash Common Dividend
- -
- -
-10.63%

Quarterly Revenue

ILS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
237
214
238
221
920
2025
238
219
228
246
931
2026
214
199
- -
- -
- -

Quarterly Earnings Per Share

ILS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.25
0.49
1.16
0.59
3.48
2025
0.81
1.51
0.98
1.66
4.97
2026
0.44
0.4
- -
- -
- -

Quarterly Dividends Per Share

ILS

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1.36
- -
- -
1.36
2025
- -
1.22
- -
- -
1.22
2026
- -
1.99
- -
- -
- -

Company Description

CEO
Moshe Ben Shaul
Full Time Employees
360
Sector
Distribution services
Industry
Medical distributors
Address
7 Hatnufa Street Petach Tikva HM Israel 4951025
IPO Date
Jan 1, 1995
Business
Ilex Medical Ltd (ILX.TA) is an Israel-based supplier of in vitro diagnostic equipment, laboratory management software, and healthcare technological solutions. The company engages in the import, marketing, distribution, and sale of diagnostic products, kits, and consumables; microbiology, chemistry, molecular biology, immunochemistry, and blood banking solutions; coagulation, hematology, blood gases, bilirubin, biomarkers, fertility, cellular medicine, occult blood, and calprotectin services; as well as LIS, urine microscopy, osmolarity, and genetic laboratory services. It also provides medical automation solutions for microbiology, immunoserology, chemistry, hematology, and coagulation; medical equipment for pain management, endoscopy systems, digestive health, cardiology, vascular interventions, radiology, care wards, radiotherapy, urology, ophthalmology, anesthesia, respiratory care, and women's health; oncogenetics, pharmacogenetics, pregnancy checks, and genetic disease testing services; single cell analysis, microbiome, epigenetics, gene expression, bioinformatics, molecular diagnostics, automated and manual DNA/RNA, and liquid biopsy solutions; and clinical ventilation products such as Vento2ux and Flight 60. Founded in 1977 and headquartered in Petah Tikva, Israel, Ilex Medical operates primarily in Israel and South Africa, with international reach, through segments including medical laboratory equipment and diagnostics materials, medical equipment, and inhalation devices; its South African subsidiary, ILEX South Africa Pty Ltd, was established in 1992 and is based in Woodmead, Gauteng. In recent developments, the company reported earnings results for the second quarter and six months ended June 30, 2025, reflecting ongoing operational performance in the healthcare distribution sector.